Low
₹8,452.50
High
₹8,670.50
| Previous Close | ₹8,493.00 |
|---|---|
| Day's Range | ₹8,452.50 - ₹8,670.50 |
| Open | ₹8,538.00 |
| 52 Week Range | ₹7,551.50 - ₹10,691.00 |
| Volume | 4,155 |
| Market Cap | ₹0.02 |
| Trade Value ( ₹ in Lacs) | 354.87 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.38 |
| Price/Earning (TTM) | 105.65 |
| TTM EPS (₹) | 80.36 |
| P/E Ratio | 185.90 |
| Book Value(₹) | 25.52 |
| PAT Margin (%) | 6.72 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 21.29 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 4402.9 | 12955.3 |
| Expenses | N/A | N/A |
| PBT | 420.2 | 2195.4 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 308.5 | 1615.1 |
| Founded | 1979 |
|---|---|
| NSE Symbol | ASTRAZEN |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,43,229.15 | 1,847.30 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,100.22 | 6,708.90 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,48,250.95 | 4,376.45 | 3,101.60 - 3,101.60 |
| Apollo Hospitals Enterprise Ltd. | 1,16,391.52 | 8,094.85 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,08,864.87 | 1,347.70 | 1,165.70 - 1,165.70 |
| Lupin Ltd. | 1,08,721.36 | 2,377.90 | 1,836.80 - 1,836.80 |
| Dr. Reddy's Laboratories Ltd. | 1,07,942.01 | 1,293.00 | 1,138.50 - 1,138.50 |
| Mankind Pharma Ltd. | 1,00,199.63 | 2,427.15 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 98,526.33 | 1,012.45 | 903.00 - 903.00 |
| Zydus Lifesciences Ltd. | 94,475.31 | 938.00 | 835.50 - 835.50 |
No Records Found
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), AstraZeneca Pharma India has informed that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Sandhya Tejaswini Amanna as Director - Legal, with effect from March 18, 2026. This being a Senior Management Personnel position in terms of the SEBI Listing Regulations, it has enclosed details as required under the SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026, attached as Annexure -A.
The above information is a part of company’s filings submitted to BSE.
AstraZeneca Pharma India has informed that it enclosed the Postal Ballot Notice dated February 11, 2026, being sent to the members of the Company to their registered email addresses, seeking their approval for the special business as set out therein. The Notice is being sent to the members whose names appear in the Register of Members/ Record of Depositories as on the cut-off date being Friday, February 20, 2026. The e-voting period commences on Saturday, February 28, 2026 (9:00 am IST) and ends on Sunday, March 29, 2026 (05:00 pm IST). The Company has engaged the services of National Securities Depository for facilitating e-voting in a secure manner. The said information is also available on the website of the Company: www.astrazeneca.com/india.
The above information is a part of company’s filings submitted to BSE.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 1164.10 | 872.06 | 33.49 | 4527.66 | 3514.11 | 28.84 | 4527.66 | 3514.11 | 28.84 |
| Other Income | 51.63 | 45.30 | 13.97 | 633.88 | 614.90 | 3.09 | 633.88 | 614.90 | 3.09 |
| PBIDT | 320.18 | 187.00 | 71.22 | 1738.22 | 1321.69 | 31.51 | 1738.22 | 1321.69 | 31.51 |
| Interest | 0.60 | 0.77 | -22.08 | 2.07 | 2.36 | -12.29 | 2.07 | 2.36 | -12.29 |
| PBDT | 319.58 | 186.23 | 71.61 | 1697.57 | 1319.33 | 28.67 | 1697.57 | 1319.33 | 28.67 |
| Depreciation | 31.15 | 31.14 | 0.03 | 120.83 | 114.05 | 5.94 | 120.83 | 114.05 | 5.94 |
| PBT | 288.43 | 155.09 | 85.98 | 1576.74 | 1205.28 | 30.82 | 1576.74 | 1205.28 | 30.82 |
| TAX | 65.48 | 44.55 | 46.98 | 258.68 | 181.08 | 42.85 | 258.68 | 181.08 | 42.85 |
| Deferred Tax | -2.22 | 9.10 | -124.40 | -12.01 | 12.22 | -198.28 | -12.01 | 12.22 | -198.28 |
| PAT | 222.95 | 110.54 | 101.69 | 1318.06 | 1024.20 | 28.69 | 1318.06 | 1024.20 | 28.69 |
| Equity | 223.85 | 223.76 | 0.04 | 223.85 | 223.76 | 0.04 | 223.85 | 223.76 | 0.04 |
| PBIDTM(%) | 27.50 | 21.44 | 28.26 | 38.39 | 37.61 | 2.07 | 38.39 | 37.61 | 2.07 |
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 1497.68 | 1354.14 | 10.60 | 5025.53 | 4518.16 | 11.23 | 5025.53 | 4518.16 | 11.23 |
| Other Income | 47.31 | 48.19 | -1.83 | 175.74 | 176.79 | -0.59 | 175.74 | 176.79 | -0.59 |
| PBIDT | 302.74 | 225.21 | 34.43 | 932.59 | 758.79 | 22.90 | 932.59 | 758.79 | 22.90 |
| Interest | 0.46 | 0.43 | 6.98 | 1.95 | 2.19 | -10.96 | 1.95 | 2.19 | -10.96 |
| PBDT | 226.23 | 224.78 | 0.65 | 842.07 | 756.60 | 11.30 | 842.07 | 756.60 | 11.30 |
| Depreciation | 16.06 | 16.22 | -0.99 | 63.19 | 65.26 | -3.17 | 63.19 | 65.26 | -3.17 |
| PBT | 210.17 | 208.56 | 0.77 | 778.88 | 691.34 | 12.66 | 778.88 | 691.34 | 12.66 |
| TAX | 48.23 | 56.78 | -15.06 | 199.70 | 182.99 | 9.13 | 199.70 | 182.99 | 9.13 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PAT | 161.94 | 151.78 | 6.69 | 579.18 | 508.35 | 13.93 | 579.18 | 508.35 | 13.93 |
| Equity | 28.91 | 28.91 | 0.00 | 28.91 | 28.91 | 0.00 | 28.91 | 28.91 | 0.00 |
| PBIDTM(%) | 20.21 | 16.63 | 21.54 | 18.56 | 16.79 | 10.50 | 18.56 | 16.79 | 10.50 |
No Records Found
The current share price of Astrazeneca Pharma India Ltd. is ₹8,493.00 as of 2026-05-08.
The market capitalisation of Astrazeneca Pharma India Ltd. is ₹21,223.12 as of 2026-05-08.
The 1-year return of Astrazeneca Pharma India Ltd. is 0.00% as of 2026-05-08.
The P/E ratio of Astrazeneca Pharma India Ltd. is 185.90 as of 2026-05-10.
The 52-week high and low of Astrazeneca Pharma India Ltd. are ₹10,691.00 and ₹7,551.50, respectively, as of 2026-05-08.
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.